Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Patients Suffering from Gaucher’s Disease Deserve Better

scientist-eyedropper

Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing a frontier of unmet medical need [NCATS, NIH]. The challenges for drug development generally—long and costly research and development timelines—are exacerbated by the inherently small patient populations affected by rare diseases. These patients can be difficult to identify and geographically dispersed and their clinical presentation can be quite disparate, complicating the design and recruitment for clinical trials used to determine Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Pennsylvania Roundtable Answers the Call for Cures

Collins and Greenwood-115x76

Congressman Joe Pitts (PA-16) recently hosted a roundtable in Lancaster to discuss how to expedite cures and treatments with leading national, regional and local health care innovators from the government, private, and public sectors, including BIO’s Jim Greenwood, Dr. Francis Collins, Director of the National Institutes of Health, and Dr. Margaret Hamburg, Commissioner for the U.S. Food and Drug Administration. The roundtable is one of many being held across the country as part of the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Pitts Sounds off on Biosimilar Naming

lab_tech

This week, the Food and Drug Law Institute published a white paper – Biosimilar Nomenclature: Can we achieve the truth, the whole truth, & nothing but the truth? – outlining key considerations around the naming of biosimilars. Peter J. Pitts, President, Center for Medicine in the Public Interest and Former Associate Commissioner, US Food and Drug Administration, asserts that ‘those who view distinctive biosimilar nomenclature naming as either contrary to safety or anti-competitive are addressing Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

4 Benefits of Plant-Made Pharmaceuticals

Synthetic Biology

For centuries, plants have served as a natural source of treatments and therapies. New advances in biotechnology make it possible to turn plants into “factories” that produce therapeutic proteins for use in the manufacture of biologics. The potential of plant-made pharmaceuticals to combat life-threatening diseases has been in the news recently as they may be helpful in treating Ebola. Developing therapeutic proteins in plants can be a safer, more efficient and cost-effective method of protein Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , ,

Promising vaccine companies set to take the stage at BIO Investor Forum

BIO Investor Forum

It is no secret that vaccines are a hot space in biotech right now, and the 13th Annual BIO Investor Forum will feature several companies working on promising vaccine R&D. The event, scheduled for October 7-8 in San Francisco, Calif., will feature 120 late-stage private and emerging public company presentations. Attendees at the BIO Investor Forum will hear from Immunovaccine, a clinical-stage vaccine development company focused on product candidates for cancer therapy, infectious disease and Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,